BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Devendra D, Eisenbarth GS. Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol. 2004;111:225-233. [PMID: 15183143 DOI: 10.1016/j.clim.2004.01.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Li B, Zhao H, Wu P, Wu Q, Chen K, Mu Y. A systematic review and meta-analysis of endocrine-related adverse events associated with interferon. Front Endocrinol 2022;13:949003. [DOI: 10.3389/fendo.2022.949003] [Reference Citation Analysis]
2 Sosnowski K, Nehring P, Przybyłkowski A. Pancreas and Adverse Drug Reactions: A Literature Review. Drug Saf 2022. [PMID: 35788538 DOI: 10.1007/s40264-022-01204-0] [Reference Citation Analysis]
3 Wang L, Chen K, Wang M, Lv Z, Gu W, Wang X, Ni Q, Mu Y. Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review. Horm Metab Res 2022;54:145-52. [PMID: 35276739 DOI: 10.1055/a-1749-5716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Benner SE, Walter DL, Thuma JR, Courreges M, James CBL, Schwartz FL, McCall KD. Toll-Like Receptor 3 Is Critical to the Pancreatic Islet Milieu That Is Required for Coxsackievirus B4-Induced Type 1 Diabetes in Female Nonobese Diabetic Mice. Pancreas 2022;51:48-55. [PMID: 35195595 DOI: 10.1097/MPA.0000000000001960] [Reference Citation Analysis]
5 Qu HQ, Qu J, Bradfield J, Marchand L, Glessner J, Chang X, March M, Li J, Connolly JJ, Roizen JD, Sleiman P, Polychronakos C, Hakonarson H. Genetic architecture of type 1 diabetes with low genetic risk score informed by 41 unreported loci. Commun Biol 2021;4:908. [PMID: 34302048 DOI: 10.1038/s42003-021-02368-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li Y, Sun F, Yue TT, Wang FX, Yang CL, Luo JH, Rong SJ, Xiong F, Zhang S, Wang CY. Revisiting the Antigen-Presenting Function of β Cells in T1D Pathogenesis. Front Immunol 2021;12:690783. [PMID: 34335595 DOI: 10.3389/fimmu.2021.690783] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
7 Liu D, Ding Q, Dai DF, Padhy B, Nayak MK, Li C, Purvis M, Jin H, Shu C, Chauhan AK, Huang CL, Attanasio M. Loss of diacylglycerol kinase ε causes thrombotic microangiopathy by impairing endothelial VEGFA signaling. JCI Insight 2021;6:146959. [PMID: 33986189 DOI: 10.1172/jci.insight.146959] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Hu P, Ming B, Wu X, Cai S, Tang J, Dong Y, Zhou T, Tan Z, Zhong J, Zheng F, Dong L. Intratracheal Poly(I:C) Exposure Accelerates the Immunological Disorder of Salivary Glands in Sjogren's-Like NOD/ShiLtJ Mice. Front Med (Lausanne) 2021;8:645816. [PMID: 33928105 DOI: 10.3389/fmed.2021.645816] [Reference Citation Analysis]
9 Wajda A, Łapczuk-Romańska J, Paradowska-Gorycka A. Epigenetic Regulations of AhR in the Aspect of Immunomodulation. Int J Mol Sci 2020;21:E6404. [PMID: 32899152 DOI: 10.3390/ijms21176404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Brown JJ, Jabri B, Dermody TS. A viral trigger for celiac disease. PLoS Pathog 2018;14:e1007181. [PMID: 30235320 DOI: 10.1371/journal.ppat.1007181] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
11 Lombardi A, Tsomos E, Hammerstad SS, Tomer Y. Interferon alpha: The key trigger of type 1 diabetes. J Autoimmun. 2018;94:7-15. [PMID: 30115527 DOI: 10.1016/j.jaut.2018.08.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
12 Lombardi A, Tomer Y. Interferon alpha impairs insulin production in human beta cells via endoplasmic reticulum stress. J Autoimmun 2017;80:48-55. [PMID: 28238527 DOI: 10.1016/j.jaut.2017.02.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
13 Khan WA. Recombinant Interferon Alpha-2b is a High-Affinity Antigen for Type 1 Diabetes Autoantibodies. Can J Diabetes 2017;41:217-23. [PMID: 28024793 DOI: 10.1016/j.jcjd.2016.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Richardson SJ, Rodriguez-Calvo T, Gerling IC, Mathews CE, Kaddis JS, Russell MA, Zeissler M, Leete P, Krogvold L, Dahl-Jørgensen K, von Herrath M, Pugliese A, Atkinson MA, Morgan NG. Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia 2016;59:2448-58. [PMID: 27506584 DOI: 10.1007/s00125-016-4067-4] [Cited by in Crossref: 122] [Cited by in F6Publishing: 127] [Article Influence: 20.3] [Reference Citation Analysis]
15 Schulte BM, Gielen PR, Kers-Rebel ED, Prosser AC, Lind K, Flodström-Tullberg M, Tack CJ, Elving LD, Adema GJ. Enterovirus Exposure Uniquely Discriminates Type 1 Diabetes Patients with a Homozygous from a Heterozygous Melanoma Differentiation-Associated Protein 5/Interferon Induced with Helicase C Domain 1 A946T Genotype. Viral Immunol 2016;29:389-97. [PMID: 27482829 DOI: 10.1089/vim.2015.0140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hotta-Iwamura C, Tarbell KV. Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment. J Leukoc Biol. 2016;100:65-80. [PMID: 26792821 DOI: 10.1189/jlb.3mr1115-500r] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
17 Motta VN, Markle JG, Gulban O, Mortin-Toth S, Liao KC, Mogridge J, Steward CA, Danska JS. Identification of the inflammasome Nlrp1b as the candidate gene conferring diabetes risk at the Idd4.1 locus in the nonobese diabetic mouse. J Immunol 2015;194:5663-73. [PMID: 25964492 DOI: 10.4049/jimmunol.1400913] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
18 Pane JA, Coulson BS. Lessons from the mouse: potential contribution of bystander lymphocyte activation by viruses to human type 1 diabetes. Diabetologia 2015;58:1149-59. [PMID: 25794781 DOI: 10.1007/s00125-015-3562-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
19 Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 2015; 21(1): 233-239 [PMID: 25574096 DOI: 10.3748/wjg.v21.i1.233] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
20 Zurawek M, Fichna M, Fichna P, Skowronska B, Dzikiewicz-Krawczyk A, Januszkiewicz D, Nowak J. Cumulative effect of IFIH1 variants and increased gene expression associated with type 1 diabetes. Diabetes Res Clin Pract 2015;107:259-66. [PMID: 25515714 DOI: 10.1016/j.diabres.2014.11.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
21 McCall KD, Thuma JR, Courreges MC, Benencia F, James CB, Malgor R, Kantake N, Mudd W, Denlinger N, Nolan B, Wen L, Schwartz FL. Toll-like receptor 3 is critical for coxsackievirus B4-induced type 1 diabetes in female NOD mice. Endocrinology 2015;156:453-61. [PMID: 25422874 DOI: 10.1210/en.2013-2006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
22 Stefan M, Wei C, Lombardi A, Li CW, Concepcion ES, Inabnet WB 3rd, Owen R, Zhang W, Tomer Y. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc Natl Acad Sci U S A 2014;111:12562-7. [PMID: 25122677 DOI: 10.1073/pnas.1408821111] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
23 Xia CQ, Peng R, Chernatynskaya AV, Yuan L, Carter C, Valentine J, Sobel E, Atkinson MA, Clare-Salzler MJ. Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production. J Immunol 2014;193:1024-34. [PMID: 24973447 DOI: 10.4049/jimmunol.1303230] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
24 Zouk H, Marchand L, Li Q, Polychronakos C. Functional characterization of the Thr946Ala SNP at the type 1 diabetes IFIH1 locus. Autoimmunity 2014;47:40-5. [PMID: 24117221 DOI: 10.3109/08916934.2013.832758] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
25 Mavragani CP, Niewold TB, Chatzigeorgiou A, Danielides S, Thomas D, Kirou KA, Kamper E, Kaltsas G, Crow MK. Increased serum type I interferon activity in organ-specific autoimmune disorders: clinical, imaging, and serological associations. Front Immunol 2013;4:238. [PMID: 23966997 DOI: 10.3389/fimmu.2013.00238] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
26 Sollid LM, Jabri B. Triggers and drivers of autoimmunity: lessons from coeliac disease. Nat Rev Immunol. 2013;13:294-302. [PMID: 23493116 DOI: 10.1038/nri3407] [Cited by in Crossref: 205] [Cited by in F6Publishing: 205] [Article Influence: 22.8] [Reference Citation Analysis]
27 Wu LH, Huang CC, Adhikarakunnathu S, San Mateo LR, Duffy KE, Rafferty P, Bugelski P, Raymond H, Deutsch H, Picha K, Ward CK, Alexoupolou L, Flavell RA, Mbow ML, Susulic VS. Loss of toll-like receptor 3 function improves glucose tolerance and reduces liver steatosis in obese mice. Metabolism 2012;61:1633-45. [DOI: 10.1016/j.metabol.2012.04.015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
28 Courreges MC, Kantake N, Goetz DJ, Schwartz FL, McCall KD. Phenylmethimazole blocks dsRNA-induced IRF3 nuclear translocation and homodimerization. Molecules 2012;17:12365-77. [PMID: 23090018 DOI: 10.3390/molecules171012365] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
29 George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135:44-53. [PMID: 22484806 DOI: 10.1016/j.pharmthera.2012.03.006] [Cited by in Crossref: 111] [Cited by in F6Publishing: 108] [Article Influence: 11.1] [Reference Citation Analysis]
30 Yagyu H, Okada K, Sato S, Yamashita Y, Okada N, Osuga J, Nagasaka S, Sugano K, Ishibashi S. Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus. Diabetes Res Clin Pract. 2012;95:e52-e54. [PMID: 22154462 DOI: 10.1016/j.diabres.2011.11.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
31 Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res 2011;31:887-92. [PMID: 21923413 DOI: 10.1089/jir.2011.0071] [Cited by in Crossref: 98] [Cited by in F6Publishing: 101] [Article Influence: 8.9] [Reference Citation Analysis]
32 Nandula SR, Scindia YM, Dey P, Bagavant H, Deshmukh US. Activation of innate immunity accelerates sialoadenitis in a mouse model for Sjögren's syndrome-like disease. Oral Dis 2011;17:801-7. [PMID: 21815968 DOI: 10.1111/j.1601-0825.2011.01839.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
33 Robinson T, Kariuki SN, Franek BS, Kumabe M, Kumar AA, Badaracco M, Mikolaitis RA, Guerrero G, Utset TO, Drevlow BE, Zaacks LS, Grober JS, Cohen LM, Kirou KA, Crow MK, Jolly M, Niewold TB. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-α and serologic autoimmunity in lupus patients. J Immunol 2011;187:1298-303. [PMID: 21705624 DOI: 10.4049/jimmunol.1100857] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 9.4] [Reference Citation Analysis]
34 Ying F, Chalise JP, Narendra SC, Magnusson M. Type I IFN protects against antigen-induced arthritis. Eur J Immunol 2011;41:1687-95. [PMID: 21469099 DOI: 10.1002/eji.201040956] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
35 Li Q, McDevitt HO. The role of interferon alpha in initiation of type I diabetes in the NOD mouse. Clin Immunol 2011;140:3-7. [PMID: 21592863 DOI: 10.1016/j.clim.2011.04.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
36 McCartney SA, Vermi W, Lonardi S, Rossini C, Otero K, Calderon B, Gilfillan S, Diamond MS, Unanue ER, Colonna M. RNA sensor-induced type I IFN prevents diabetes caused by a β cell-tropic virus in mice. J Clin Invest 2011;121:1497-507. [PMID: 21403398 DOI: 10.1172/JCI44005] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 4.9] [Reference Citation Analysis]
37 Lau-Kilby AW, Kretz CC, Pechhold S, Price JD, Dorta S, Ramos H, Trinchieri G, Tarbell KV. Interleukin-2 inhibits FMS-like tyrosine kinase 3 receptor ligand (flt3L)-dependent development and function of conventional and plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 2011;108:2408-13. [PMID: 21262836 DOI: 10.1073/pnas.1009738108] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
38 Van Belle TL, Coppieters KT, Von Herrath MG. Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies. Physiological Reviews 2011;91:79-118. [DOI: 10.1152/physrev.00003.2010] [Cited by in Crossref: 582] [Cited by in F6Publishing: 572] [Article Influence: 52.9] [Reference Citation Analysis]
39 Jaïdane H, Sauter P, Sane F, Goffard A, Gharbi J, Hober D. Enteroviruses and type 1 diabetes: towards a better understanding of the relationship. Rev Med Virol. 2010;20:265-280. [PMID: 20629044 DOI: 10.1002/rmv.647] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 5.1] [Reference Citation Analysis]
40 Csorba TR, Lyon AW, Hollenberg MD. Autoimmunity and the pathogenesis of type 1 diabetes. Critical Reviews in Clinical Laboratory Sciences 2010;47:51-71. [DOI: 10.3109/10408361003787171] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
41 Gaffney PM, Moser KL, Baechler EC. Defining a new molecular basis of systemic lupus erythematosus through transcriptional profiling. Expert Rev Clin Immunol 2007;3:913-23. [PMID: 20477140 DOI: 10.1586/1744666X.3.6.913] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Todd JA. Etiology of type 1 diabetes. Immunity. 2010;32:457-467. [PMID: 20412756 DOI: 10.1016/j.immuni.2010.04.001] [Cited by in Crossref: 340] [Cited by in F6Publishing: 321] [Article Influence: 28.3] [Reference Citation Analysis]
43 Chistiakov DA. Interferon induced with helicase C domain 1 (IFIH1) and virus-induced autoimmunity: a review. Viral Immunol 2010;23:3-15. [PMID: 20121398 DOI: 10.1089/vim.2009.0071] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
44 Kariuki SN, Crow MK, Niewold TB. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum 2008;58:2818-23. [PMID: 18759295 DOI: 10.1002/art.23728] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 5.6] [Reference Citation Analysis]
45 Mackensen F, Max R, Becker MD. Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol 2009;3:559-66. [PMID: 19898628 DOI: 10.2147/opth.s3308] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
46 Kariuki SN, Niewold TB. Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl Res 2010;155:109-17. [PMID: 20171594 DOI: 10.1016/j.trsl.2009.08.012] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
47 García M, Dogusan Z, Moore F, Sato S, Hartmann G, Eizirik DL, Rasschaert J. Regulation and function of the cytosolic viral RNA sensor RIG-I in pancreatic beta cells. Biochim Biophys Acta 2009;1793:1768-75. [PMID: 19747951 DOI: 10.1016/j.bbamcr.2009.09.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
48 Hass HG, Klein R, Nehls O, Kaiser S. Thyroid disorders and occurrence of nonorgan-specific autoantibodies (NOSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1). J Clin Gastroenterol. 2009;43:470-476. [PMID: 19247202 DOI: 10.1097/mcg.0b013e318184a470] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
49 Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H. Dual onset of type 1 diabetes mellitus and Graves’ disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Diabetes Res Clin Pract. 2009;86:e19-e21. [PMID: 19744739 DOI: 10.1016/j.diabres.2009.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
50 Coppieters KT, von Herrath MG. Histopathology of type 1 diabetes: old paradigms and new insights. Rev Diabet Stud 2009;6:85-96. [PMID: 19806238 DOI: 10.1900/RDS.2009.6.85] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
51 Wagner B, Hillegas JM, Flaminio MJB, Wattrang E. Monoclonal antibodies to equine interferon-α (IFN-α): New tools to neutralize IFN-activity and to detect secreted IFN-α. Veterinary Immunology and Immunopathology 2008;125:315-25. [DOI: 10.1016/j.vetimm.2008.05.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
52 Field J, Alderuccio F, Hertzog P, Toh BH. GM-CSF-induced autoimmune gastritis in interferon alpha receptor deficient mice. J Autoimmun 2008;31:274-80. [PMID: 18501559 DOI: 10.1016/j.jaut.2008.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
53 Nylen ES, Marathe IC, Khan IA, Azevedo R, Hirsch KR. Sudden onset of diabetic ketoacidosis during consensus interferon therapy for chronic viral hepatitis C. Am J Med Sci 2008;335:329-30. [PMID: 18414077 DOI: 10.1097/MAJ.0b013e318145a721] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
54 Coelho LF, de Oliveira JG, Kroon EG. Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma? Immunol Lett 2008;118:110-5. [PMID: 18499269 DOI: 10.1016/j.imlet.2008.03.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
55 Schreuder TC, Gelderblom HC, Weegink CJ, Hamann D, Reesink HW, Devries JH, Hoekstra JB, Jansen PL. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int. 2008;28:39-46. [PMID: 18031478 DOI: 10.1111/j.1478-3231.2007.01610.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
56 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
57 Mackensen F, Max R, Becker MD. Interferon therapy for ocular disease. Current Opinion in Ophthalmology 2006;17:567-73. [DOI: 10.1097/icu.0b013e328010ab35] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
58 Mahieu T, Libert C. Should we inhibit type I interferons in sepsis? Infect Immun 2007;75:22-9. [PMID: 17000722 DOI: 10.1128/IAI.00829-06] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
59 Summers KL, Marleau AM, Mahon JL, McManus R, Hramiak I, Singh B. Reduced IFN-alpha secretion by blood dendritic cells in human diabetes. Clin Immunol. 2006;121:81-89. [PMID: 16859998 DOI: 10.1016/j.clim.2006.05.015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 2.4] [Reference Citation Analysis]
60 Harris PE, Malanga D, Liu Z, Hardy MA, Souza F, Del Pozzo G, Winchester RJ, Maffei A. Effect of interferon alpha on MHC class II gene expression in ex vivo human islet tissue. Biochim Biophys Acta 2006;1762:627-35. [PMID: 16782520 DOI: 10.1016/j.bbadis.2006.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
61 Nordmark G, Alm GV, Rönnblom L. Mechanisms of Disease: primary Sjögren's syndrome and the type I interferon system. Nat Rev Rheumatol 2006;2:262-9. [DOI: 10.1038/ncprheum0173] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
62 Thornley TB, Brehm MA, Markees TG, Shultz LD, Mordes JP, Welsh RM, Rossini AA, Greiner DL. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol 2006;176:1561-70. [PMID: 16424185 DOI: 10.4049/jimmunol.176.3.1561] [Cited by in Crossref: 101] [Cited by in F6Publishing: 97] [Article Influence: 6.3] [Reference Citation Analysis]
63 Ivakine EA, Gulban OM, Mortin-toth SM, Wankiewicz E, Scott C, Spurrell D, Canty A, Danska JS. Molecular Genetic Analysis of the Idd4 Locus Implicates the IFN Response in Type 1 Diabetes Susceptibility in Nonobese Diabetic Mice. J Immunol 2006;176:2976-90. [DOI: 10.4049/jimmunol.176.5.2976] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
64 Aly T, Devendra D, Eisenbarth GS. Immunotherapeutic approaches to prevent, ameliorate, and cure type 1 diabetes. Am J Ther 2005;12:481-90. [PMID: 16280641 DOI: 10.1097/01.mjt.0000178782.97413.79] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
65 . Human monoclonal antibodies to IFN-α for the treatment of autoimmune diseases: Medarex, Inc.: WO2005059106. Expert Opinion on Therapeutic Patents 2006;16:221-6. [DOI: 10.1517/13543776.16.2.221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
66 Bopegamage S, Kovacova J, Vargova A, Motusova J, Petrovicova A, Benkovicova M, Gomolcak P, Bakkers J, van Kuppeveld F, Melchers WJG, Galama JM. Coxsackie B virus infection of mice: inoculation by the oral route protects the pancreas from damage, but not from infection. J Gen Virol 2005;86:3271-80. [PMID: 16298972 DOI: 10.1099/vir.0.81249-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
67 Kohn LD, Wallace B, Schwartz F, McCall K. Is type 2 diabetes an autoimmune-inflammatory disorder of the innate immune system? Endocrinology 2005;146:4189-91. [PMID: 16166230 DOI: 10.1210/en.2005-0920] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
68 Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev. 2005;204:232-249. [PMID: 15790362 DOI: 10.1111/j.0105-2896.2005.00248.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 68] [Article Influence: 5.3] [Reference Citation Analysis]
69 Christen U, Herrath MGV. Initiation of autoimmunity. Current Opinion in Immunology 2004;16:759-67. [DOI: 10.1016/j.coi.2004.09.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
70 Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ 2004;328:750-4. [PMID: 15044291 DOI: 10.1136/bmj.328.7442.750] [Cited by in Crossref: 170] [Cited by in F6Publishing: 151] [Article Influence: 9.4] [Reference Citation Analysis]